BioCentury
ARTICLE | Company News

GNSC, AZN genomics deal

December 11, 2001 8:00 AM UTC

Genaissance (GNSC) granted AstraZeneca (AZN; LSE:AZN) access to its Hap Markers technology, which is used to predict drug safety and efficacy, for use in an undisclosed AZN target discovery program. A...